Navigation Links
Selexis SA Names Dr. Marco Bocci Director of European Sales and Business Development
Date:11/19/2013

Geneva, Switzerland (PRWEB) November 19, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the hire of Marco Bocci, PhD, DPharm, as Director of European Sales and Business Development. Dr. Bocci joins Selexis from Quintiles and will be responsible for growing and managing sales and business development in Europe.

“With the recent launch of our SURE CHO-Mplus Libaries, Selexis is now well positioned to meet our customers biologic development needs from discovery to commercial manufacturing,” said Dr. Igor Fisch, CEO of Selexis SA. “The addition of Marco to our leadership team underscores our commitment to helping our customers discover and commercialize biologic therapeutics. Marco’s knowledge of the CRO field and the scientific skills he acquired at the University of Cambridge are the right fit for our growing technology platform and customer base.”

Dr. Bocci brings a proven track record in business development, sales and clinical development. With over 15 years of experience in life sciences, Dr. Bocci has extensive international business, product development and regulatory knowledge gained within the biotechnology and clinical research industries. Prior to joining Selexis, he was with Quintiles Outcome as Business Development Director where he focused on increasing European market penetration and building new customer relationships. Before joining the industry, Dr. Bocci did his postdoctoral studies at the Medical Research Council (MRC) in Cambridge, UK. He obtained his PhD from the University of Cambridge and is also a trained pharmacist.

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Read the full story at http://www.prweb.com/releases/Marco_Bocci_Selexis/cell_line_development/prweb11344577.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
2. Selexis SA to Present and Partner at the BIO-Europe Spring
3. Selexis SA to Partner and Exhibit at BIO 2013
4. Selexis SA Launches SURE CHO-Mplus™ Libraries
5. Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering
6. Advancement in Biologic Protein Expression Webinar Hosted by Selexis SA
7. Selexis SA to Present Data on Improved Selection of Recombinant Protein Production Clones at the Bioprocessing Summit 2013
8. Selexis SA to Present and Partner at the BIO-Europe 2013 Partnering Conference
9. Kessler Foundation names Dr. John Whyte recipient of Foundations 2nd Annual DeLisa Award
10. US Drug Watchdog Now Urges All Recalled DePuy ASR Hip Implant Recipients Call Them For The Names Of The Best Attorneys Out Of Fear The Recipients Will Get Nothing
11. US Drug Watchdog Launches Now Calls Transvaginal Mesh A Disaster For 100,000's of US Women Recipients And Offers The Names and Contacts Of The Best Women Attorneys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... DIEGO, California (PRWEB) , ... June 20, 2017 ... ... product documentation and help content solutions for the enterprise, is proud to announce ... properties, including CRM, e-commerce, ticketing systems, company websites, and more to provide a ...
(Date:6/20/2017)... Cincinnati, Ohio (PRWEB) , ... June 20, 2017 ... ... with gum disease in Cincinnati, OH for leading-edge care, whether or ... advances in laser dentistry. Using the BIOLASE WaterLase® iPlus™ laser, she targets bacteria ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience ... in Denville, NJ, Drs. Adam and Hal Kimowitz are currently accepting new patients at ... traditional orthodontics can cause for some patients, which is why they offer the latest ...
(Date:6/20/2017)... ... June 20, 2017 , ... This year, participants ... focused on finding product improvements that could reduce the occurrence of unplanned extubations ... need help breathing or to provide medication. Sometimes, patient movement can cause unplanned ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... makers of SweetLeaf® Stevia Sweetener, Michael P. May, Ph.D., recently accepted the distinguished ... Export Recognition Program selected Wisdom Natural Brands (WNB), and 16 other businesses from ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... June 12, 2017 Kineta, Inc., a biotechnology company ... Kineta Vice President of R&D and Head of Virology ... Pandemic Preparedness for the Northwest and Beyond meeting sponsored ... June 14, 2017 from 8:30-10:30 AM PDT at the Agora ... Dr. Bedard will be joined by other leaders ...
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/7/2017)... June 6, 2017  Diplomat Specialty Infusion Group, a brand of ... to its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound ... a low level of pollutants. ... consumers and better serve our Iowa patients," ...
Breaking Medicine Technology: